Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug Delivery

Gael Touya, President and CEO of Aptar

“The acquisition of PULMOTREE is an important step in expanding Aptar Pharma’s leadership in respiratory drug delivery and broadening the opportunities we can address with our pharmaceutical partners”

Gael Touya, President and CEO of Aptar

“Kolibri™ brings a differentiated technology to our portfolio with the potential to support increasingly complex inhaled therapies, including biologics.”

Gael Touya, President and CEO of Aptar

“By combining this platform with Aptar Pharma’s formulation, device development, regulatory, manufacturing and patient-support capabilities, we can help customers move innovative therapies from development toward commercialization while creating new avenues for long-term growth.”

Jonathan Mulpas, Director of Business Development, Pulmonary Category, Aptar Pharma

“Our collaboration with PULMOTREE over the past two years has enabled pharmaceutical partners to evaluate and gain hands-on experience with the Kolibri™ platform.”

Jonathan Mulpas, Director of Business Development, Pulmonary Category, Aptar Pharma

“The interest we have seen reinforces our belief that there is a need for this differentiated patient-centric technology designed to support the next generation of inhaled therapies.”

Ulf Krüger, CEO of PULMOTREE

“The partnership between PULMOTREE and Aptar Pharma has been built on close, trust-based collaboration, and joining Aptar is the natural next step on that shared path.”

Ulf Krüger, CEO of PULMOTREE

“For our customers and partners, this acquisition is intended to provide continuity in the technology - now backed by the reach and resources of a global organization.”